Open-label pilot study of tofacitinib 2% for the treatment of refractory vitiligo

Br J Dermatol. 2020 Apr;182(4):1047-1049. doi: 10.1111/bjd.18606. Epub 2019 Dec 5.

Authors

P Mobasher¹, R Guerra², S J Li², J Frangos², A K Ganesan¹, V Huang^{2

3}

Affiliations

¹ University of California, Irvine, Department of Dermatology, Irvine, CA, U.S.A.
² Brigham and Women's Hospital, Department of Dermatology, Boston, MA, U.S.A.
³ University of California, Davis, Department of Dermatology, Sacramento, CA, U.S.A.

No abstract available

Publication types

Clinical Study
Letter

MeSH terms

Humans
Pilot Projects
Piperidines
Protein Kinase Inhibitors
Pyrimidines
Pyrroles
Treatment Outcome
Vitiligo* / drug therapy

Substances

Piperidines
Protein Kinase Inhibitors
Pyrimidines
Pyrroles
tofacitinib

Grants and funding